Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
16 pending office actions • 15 clients • 16 examiners • 15 art units • 0 of 16 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Entralta is a patent law firm specializing in Biotechnology & Pharmaceuticals. The firm has processed 789 career applications, showing a focused history of filings in its main technology area. It maintains a resolved allowance rate of 82.6 percent, which highlights its effectiveness in obtaining patent grants for its clients. This performance metric is a key indicator of its standing in the Biotechnology & Pharmaceuticals sector. The firm's track record is well-established through its application volume.
The firm currently has 15 pending office actions under management. Its prosecution efficiency is reflected in an average of 2.68 office actions per allowance. This figure suggests a relatively streamlined path through the examination process. These statistics provide a comprehensive overview of the firm's experience and success, based on its 789 career applications. The 82.6 percent allowance rate and 2.68 average office actions per allowance offer a clear picture of its operational results. These data points are essential for understanding the firm's impact in Biotechnology & Pharmaceuticals.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (12%) |
| §103 only | 3 (19%) |
| Double-patenting + other | 3 (19%) |
| Multi-statute (no §101) | 8 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILLIGAN, CHRISTOPHER L | 1 | 57.7% | +40.0% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
| LAWSON, STACY N | 1 | 62.2% | +51.7% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
| ARON, KIMBERLY A | 1 | 54.5% | +35.2% |
| NGUYEN, SON T | 1 | 28.9% | +16.3% |
| ROTONDI, CONNOR JON | 1 | 0.0% | +0.0% |
| WHITTINGTON, JESS G | 1 | 72.8% | +17.8% |
| CHANG, KYUNG SOOK | 1 | 60.4% | +40.9% |
| SWIFT, CANDICE LEE | 1 | 57.5% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19077031 | AGENTIC ARTIFICIAL INTELLIGENCE SYSTEM FOR AUTOMATED COMPLETION OF HEALTHCARE PROCESSES | GILLIGAN, CHRISTOPHER L | — |
| 18858722 | FORMULATION FOR TREATING URINARY SYSTEM DISORDERS | SCOTLAND, REBECCA LYNN | — |
| 18901273 | EMBEDDED INFILTRATION DEVICE | LAWSON, STACY N | — |
| 18760919 | AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY | ARON, KIMBERLY A | — |
| 18581367 | HIGH EFFICIENCY PLANTER SYSTEM AND METHOD | NGUYEN, SON T | — |
| 18442273 | PASSIVE AEROBIC TREATMENT UNIT AND METHOD OF USE | ROTONDI, CONNOR JON | — |
| 18349884 | AIRWAY DEVICE | PINDERSKI, JACQUELINE M | — |
| 18030996 | NANOPARTICLE FOR ANTI-CANCER PEPTIDES AND USES THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285645 | FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS | CHANG, KYUNG SOOK | 86d overdue |
| 18770847 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATING, RELIEVING, OR ALLEVIATING ALZHEIMER'S DISEASE | CHERNYSHEV, OLGA N | 28d |
| 19077031 | AGENTIC ARTIFICIAL INTELLIGENCE SYSTEM FOR AUTOMATED COMPLETION OF HEALTHCARE PROCESSES | GILLIGAN, CHRISTOPHER L | — |
| 18901273 | EMBEDDED INFILTRATION DEVICE | LAWSON, STACY N | — |
| 18760919 | AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY | ARON, KIMBERLY A | — |
| 18581367 | HIGH EFFICIENCY PLANTER SYSTEM AND METHOD | NGUYEN, SON T | — |
| 18407211 | MOBILE TRANSPORT SYSTEM AND METHOD FOR DELIVERING ITEMS AND SERVICES | WHITTINGTON, JESS G | — |
| 18285641 | BIOACTIVE PRODUCTS | SWIFT, CANDICE LEE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| WAIHOME LLC | 2 |
| Optrahealth Inc. | 1 |
| Watershed Medical, Inc. | 1 |
| Biomed Industries | 1 |
| OCULOGENEX INC. | 1 |
| Meb Holdings LLC | 1 |
| Bib Technologies, Inc. | 1 |
| WATERSHED MEDICAL INC | 1 |
| Victor Tets | 1 |
| Kb Pro, LLC | 1 |
| InnoMed Technologies, Inc. | 1 |
| King's College London | 1 |
| CLS THERAPEUTICS LIMITED | 1 |
| Entopsis, Inc. | 1 |
| Sun Medical Technology Research | 1 |
| Art Unit | Apps |
|---|---|
| 3683 | 1 |
| 1615 | 1 |
| 3678 | 1 |
| 1675 | 1 |
| 3643 | 1 |
| 1779 | 1 |
| 3666 | 1 |
| 1613 | 1 |
| 1657 | 1 |
| 3785 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19077031 | AGENTIC ARTIFICIAL INTELLIGENCE SYSTEM FOR AUTOMATED COMPLETION OF HEALTHCARE PROCESSES | Optrahealth Inc. | GILLIGAN, CHRISTOPHER L | 3683 | §101§103§112 | Non-Final OA | — | Pending | Mar 11, 2025 |
| 18858722 | FORMULATION FOR TREATING URINARY SYSTEM DISORDERS | Watershed Medical, Inc. | SCOTLAND, REBECCA LYNN | 1615 | §102§103§112Other | Non-Final OA | — | Pending | Oct 21, 2024 |
| 18901273 | EMBEDDED INFILTRATION DEVICE | Waihome LLC | LAWSON, STACY N | 3678 | §103§112 | Final Rejection | — | Pending | Sep 30, 2024 |
| 18770847 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATING, RELIEVING, OR ALLEVIATING ALZHEIMER'S DISEASE | BIOMED INDUSTRIES, INC. | CHERNYSHEV, OLGA N | 1675 | §102DP | Final Rejection | 28d | Pending | Jul 12, 2024 |
| 18760919 | AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY | Oculogenex Inc. | ARON, KIMBERLY A | §102§112 | Non-Final OA | — | Pending | Jul 01, 2024 | |
| 18581367 | HIGH EFFICIENCY PLANTER SYSTEM AND METHOD | Meb Holdings LLC | NGUYEN, SON T | 3643 | §102§103 | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18442273 | PASSIVE AEROBIC TREATMENT UNIT AND METHOD OF USE | Waihome LLC | ROTONDI, CONNOR JON | 1779 | §102§103§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18407211 | MOBILE TRANSPORT SYSTEM AND METHOD FOR DELIVERING ITEMS AND SERVICES | Bib Technologies, Inc. | WHITTINGTON, JESS G | 3666 | §103Other | Final Rejection | — | Pending | Jan 08, 2024 |
| 18285645 | FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS | Watershed Medical Inc. | CHANG, KYUNG SOOK | 1613 | §103§112DP | Final Rejection | 86d overdue | Pending | Oct 04, 2023 |
| 18285641 | BIOACTIVE PRODUCTS | Victor Tets | SWIFT, CANDICE LEE | 1657 | §102§103§112DP | Non-Final OA | — | Pending | Oct 04, 2023 |
| 18349884 | AIRWAY DEVICE | Kb Pro, LLC | PINDERSKI, JACQUELINE M | 3785 | §102§103§112 | Non-Final OA | — | Pending | Jul 10, 2023 |
| 18306099 | FORMULATIONS CONTAINING ERYTHRITOL AND COMBINATION SKIN THERAPIES | Innomed Technologies, Inc. | WELLES, COLMAN THOMAS | 1612 | §103Other | Final Rejection | 5d | Pending | Apr 24, 2023 |
| 18030996 | NANOPARTICLE FOR ANTI-CANCER PEPTIDES AND USES THEREOF | King'S College London | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112Other | Non-Final OA | — | Pending | Apr 08, 2023 |
| 17626616 | TREATMENT OF DISEASES ASSOCIATED WITH PROTEIN MISFOLDING BY NERVOUS SYSTEM EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY | Cls Therapeutics Limited | WEN, SHARON X | 1641 | §103Other | Final Rejection | 9d | Pending | Jan 12, 2022 |
| 17472370 | DETECTABLE ARRAYS, SYSTEMS FOR DIAGNOSIS, AND METHODS OF MAKING AND USING THE SAME | Entopsis, Inc. | BUNKER, AMY M | 1684 | §101§103 | Final Rejection | — | Pending | Sep 10, 2021 |
| 16333914 | HEART CANNULA | Sun Medical Technology Research | GHAND, JENNIFER LEIGH-STEWAR | 3796 | §103§112 | Non-Final OA | — | Pending | Mar 15, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial